NextCure (NXTC) Stock Overview
A clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
NXTC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NextCure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.28 |
| 52 Week High | US$15.74 |
| 52 Week Low | US$2.69 |
| Beta | 1.54 |
| 1 Month Change | 10.34% |
| 3 Month Change | 127.40% |
| 1 Year Change | 34.55% |
| 3 Year Change | -31.69% |
| 5 Year Change | -90.22% |
| Change since IPO | -94.44% |
Recent News & Updates
Recent updates
Here's Why NextCure (NASDAQ:NXTC) Must Use Its Cash Wisely
Oct 18
Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation
Nov 13We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Jul 17We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Mar 23We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Dec 09Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?
Aug 23Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
May 10We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Nov 22Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)
Aug 09NextCure GAAP EPS of -$0.59
Aug 04We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate
May 02NextCure: Large Upside With Downside Protected By Cash Pile
Sep 29Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like
Feb 12NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares
Jan 08Shareholder Returns
| NXTC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.0% | -2.0% | -1.1% |
| 1Y | 34.5% | 22.9% | 14.7% |
Return vs Industry: NXTC exceeded the US Biotechs industry which returned 23% over the past year.
Return vs Market: NXTC exceeded the US Market which returned 14.6% over the past year.
Price Volatility
| NXTC volatility | |
|---|---|
| NXTC Average Weekly Movement | 21.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NXTC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NXTC's weekly volatility has increased from 15% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 43 | Michael Richman | www.nextcure.com |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures.
NextCure, Inc. Fundamentals Summary
| NXTC fundamental statistics | |
|---|---|
| Market cap | US$49.74m |
| Earnings (TTM) | -US$58.01m |
| Revenue (TTM) | n/a |
Is NXTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXTC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$58.01m |
| Earnings | -US$58.01m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -16.55 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NXTC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 11:56 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NextCure, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aydin Huseynov | Benchmark Company |
| Alec Stranahan | BofA Global Research |
| Reni Benjamin | Citizens JMP Securities, LLC |